Skip to main content

Edelman Joseph's Form 4 filing

Cerevel Therapeutics Holdings, Inc. (CERE) · filed Aug 18, 2022

Accession no.
0001062993-22-018390
Filed
Aug 18, 2022, 5:10 PM ET
Trade date
Aug 16, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $49.9M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Edelman JosephCIK 0001164426Director
Perceptive Advisors LLCCIK 0001224962Director
Perceptive Life Sciences Master Fund LtdCIK 0001249675Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 16, 2022Common StockPPurchaseAcquired+1,425,000$35.00+$49,875,0006,511,727Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 16, 2022Common StockPPurchaseAcquired+2,156,102$100,000,000.00––IndirectPrice outlier

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)